BEN-MAIMON CAROLE — SEC Form 4 filings
SEC reporting owner CIK 1529611. 3 Form 4 filings on record with FilingPulse; latest filed 2026-01-27.
Transaction summary — filings shown
Covers all 3 filings on record, filed 2024-01-19 to 2026-01-27. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 6.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Larimar Therapeutics, Inc. (LRMR) | President and CEO, Director | 3 | — | — | 6 |
Form 4 filings — BEN-MAIMON CAROLE
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-01-27 | 4 | Larimar Therapeutics, Inc. (LRMR) | Grant/award (A): 100,100 @ $0 · Grant/award (A): 600,600 (derivative) @ $0 | EDGAR |
| 2025-01-24 | 4 | Larimar Therapeutics, Inc. (LRMR) | Grant/award (A): 91,000 @ $0 · Grant/award (A): 546,000 (derivative) @ $0 | EDGAR |
| 2024-01-19 | 4 | Larimar Therapeutics, Inc. (LRMR) | Grant/award (A): 66,125 @ $0 · Grant/award (A): 396,750 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1529611 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →